Charge-Reversed Lipid Nanoparticles Containing Metal-Organic Cages for In Vivo Anti-Cancer Treatment

Introduction: Since the discovery and clinical success of the first inorganic anti-cancer drug cisplatin, research on more potent, selective, and multi-functional metallodrugs has progressed (1). A new metal-organic cage (MOCs) was developed recently, showing a roughly 12-fold higher anti-cancer activity in PC3 prostate cancer cells compared to cisplatin. However, rapid extravasation and clearance through the kidney were observed in zebrafish embryos (2). Therefore, we encapsulated these MOCs in lipid nanoparticles (LNPs) to improve their biodistribution and thus enable targeted anticancer activity in vivo.